<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01172821</url>
  </required_header>
  <id_info>
    <org_study_id>205.419</org_study_id>
    <secondary_id>2009-018005-43</secondary_id>
    <nct_id>NCT01172821</nct_id>
  </id_info>
  <brief_title>Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II</brief_title>
  <official_title>A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over
      a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily).
      Tiotropium inhalation solution delivered by the Respimat® inhaler will be examined on top of
      maintenance treatment with inhaled corticosteroid controller medication in patients with
      moderate persistent asthma. Efficacy and safety will be assessed by measuring effects on lung
      function, effects on asthma exacerbations, effects on quality of life, effects on asthma
      control, effects on health care resource utilisation, and number of adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak FEV1 Within 3 Hours Post-dose Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Peak forced expiratory volume in one second (FEV1) response within 3 hours post-dose determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough FEV1 Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Trough FEV1 response determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Responder Rate as Assessed by the ACQ From the Two Twin Trials 205.418 (NCT01172808) and the Present 205.419 (NCT01172821)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The responder rate as assessed by the Asthma Control Questionnaire (ACQ) determined at the end of the 24-week treatment period (on combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)). A patient was considered to be a responder if he or she was reported with an improvement (decrease) in the ACQ total score of at least 0.5 points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FVC Within 3 Hours Post-dose Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Peak forced vital capacity (FVC) response within 3 hours post-dose determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Trough FVC response determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 Area Under Curve 0-3 Hours (AUC0-3h) Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2) determined at the end of the 24- week treatment. Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC Area Under Curve 0-3 Hours (AUC0-3h) Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2) determined at the end of the 24- week treatment. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough PEF Response</measure>
    <time_frame>24 weeks</time_frame>
    <description>Trough peak expiratory flow (PEF) response determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Asthma Quality of Life Questionnaire (AQLQs)) Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Total score from the Standardised Asthma Quality of Life Questionnaire (AQLQ(s)) determined at the end of 24-week treatment.
The AQLQ(s) contains 32 questions, each question has a 7 point scale from 1 (highest intensity) till 7 (no symptoms). Total score was defined as the sum of all items divided by the number of items and ranges from from 1 (highest intensity) till 7 (no symptoms). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Asthma Control Questionnaire (ACQ) Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Control of asthma as assessed by the ACQ determined at the end of 24-week treatment. The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items and ranges from from 0 (no symptoms) till 6 (highest intensity). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Responder Rate as Assessed by the ACQ</measure>
    <time_frame>24 weeks</time_frame>
    <description>The responder rate as assessed by the Asthma Control Questionnaire (ACQ) determined at the end of the 24-week treatment period. A patient was considered to be a responder if he or she was reported with an improvement (decrease) in ACQ total score of at least 0.5 points.The score ranges from 0 (no impairment) to 6 (maximum impairment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Morning PEF (PEF a.m.) Based on the Weekly Mean Response at Week 24</measure>
    <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
    <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Evening PEF (PEF p.m.) Based on the Weekly Mean Response at Week 24</measure>
    <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
    <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEF Variability</measure>
    <time_frame>Last 7 days before week 24 visit</time_frame>
    <description>PEF daily variability was assesed by patients at home using the AM3 device. PEF variability is the absolute difference between morning and evening PEF value divided by their mean, based on the weekly mean response at week 24. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Morning FEV1 (FEV1 a.m.) Based on the Weekly Mean Response at Week 24</measure>
    <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
    <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pre-dose Evening FEV1 (FEV1 p.m.) Based on the Weekly Mean Response at Week 24</measure>
    <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
    <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Puffs of Rescue Medication During the Entire 24-h Day Based on the Weekly Mean Response at Week 24</measure>
    <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
    <description>Daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom-free Days Based on the Weekly Mean Response at Week 24</measure>
    <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
    <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week. An asthma symptom-free day was defined as a day with no reported symptoms and no use of rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Severe Asthma Exacerbation From the Two Twin Trials 205.418 (NCT01172808) and the Present 205.419 (NCT01172821)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Time to first severe asthma exacerbation during the 24-week treatment period on combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Asthma Exacerbation From the Two Twin Trials 205.418 (NCT01172808) and the Present 205.419 (NCT01172821)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Time to first asthma exacerbation (including severe, non-severe; symptomatic, asymptomatic; i.e. any exacerbation) during the 24-week treatment period on combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1032</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>tiotropium low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mcg salmeterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo that represents BI drug</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo that represents comparator</description>
    <arm_group_label>tiotropium low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo that represents comparator</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium Respimat® low dose</intervention_name>
    <description>IMP</description>
    <arm_group_label>tiotropium low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo that represents BI drug</description>
    <arm_group_label>50 mcg salmeterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium Respimat® high dose</intervention_name>
    <description>IMP</description>
    <arm_group_label>tiotropium high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mcg salmeterol HFA MDI</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>50 mcg salmeterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo that represents comparator</description>
    <arm_group_label>tiotropium high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. All patients must sign and date an Informed Consent Form consistent with International
             Conference on Harmonisation - Good Clinical Practice (ICH-GCP) guidelines and local
             legislation prior to participation in the trial (i.e. prior to any trial procedures,
             including any pre-trial washout of medications and medication restrictions for
             pulmonary function test at Visit 1).

          2. Male or female patients aged at least 18 years but not more than 75 years.

          3. All patients must have at least a 3 month history of asthma at the time of enrolment
             into the trial. The diagnosis should be confirmed at Visit 1 by fulfilling inclusion
             criterion 5.

          4. The initial diagnosis of asthma must have been made before the patient's age of 40.

          5. The diagnosis of asthma has to be confirmed at Visit 1 with a bronchodilator
             reversibility (15 minutes after 400 mcg salbutamol (albuterol)) resulting in a Forced
             Expiratory Volume in one second (FEV1) increase of at least 12% and at least 200mL.

          6. All patients must have been on maintenance treatment with a medium, stable dose of
             inhaled corticosteroids for at least for 4 weeks prior to Visit 1. 7. All patients
             must be symptomatic at Visit 1 (screening) and prior to randomisation at Visit 2 as
             defined by an Asthma Control Questionnaire (ACQ) mean score of at least 1.5.

        8. All patients must have a pre-bronchodilator FEV1 at least 60% and less than or equal to
        90% of predicted normal at Visit 1.

        9. Variation of absolute FEV1 values of Visit 1 (pre-bronchodilator) as compared to Visit 2
        (pre-dose) must be within ± 30%.

        10. Patients must be never-smokers or ex-smokers who stopped smoking at least one year
        prior to enrolment (Visit 0) and who have a smoking history of less than 10 pack years.

        11. Patients must be able to use the Respimat® inhaler and metered dose inhaler correctly.

        12. Patients must be able to perform all trial related procedures including technically
        acceptable pulmonary function tests and use of electronic diary/peak flow meter.

        Exclusion criteria:

          1. Patients with a significant disease other than asthma. A significant disease is
             defined as a disease which, in the opinion of the investigator, may (i) put the
             patient at risk because of participation in the trial, or (ii) influence the results
             of the trial, or (iii) cause concern regarding the patient's ability to participate in
             the trial.

          2. Patients with a clinically relevant abnormal screening (Visit 1) haematology or blood
             chemistry if the abnormality defines a significant disease as defined in exclusion
             criterion 1.

          3. Patients with a recent history (i.e. six months or less) of myocardial infarction.

          4. Patients who have been hospitalised for cardiac failure during the past year.

          5. Patients with any unstable or life-threatening cardiac arrhythmia or cardiac
             arrhythmia requiring intervention or a change in drug therapy within the past year.

          6. Patients with lung diseases other than asthma (e.g. Chronic Obstructive Pulmonary
             Disease (COPD)).

          7. Patients with known active tuberculosis.

          8. Patients with malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years. Patients with treated basal cell
             carcinoma are allowed.

          9. Patients who have undergone thoracotomy with pulmonary resection. Patients with a
             history of thoracotomy for other reasons should be evaluated as per exclusion
             criterion no. 1.

         10. Patients with significant alcohol or drug abuse within the past two years.

         11. Patients who are currently in a pulmonary rehabilitation program or have completed a
             pulmonary rehabilitation program in the 6 weeks prior to Visit 1 (screening).

         12. Patients with known hypersensitivity to anticholinergic drugs, benzalkonium chloride
             (BAC), ethylenediamineteraacetic acid (EDTA), salmeterol xinafoate or any other
             components of the study medication delivery systems.

         13. Pregnant or nursing woman.

         14. Women of childbearing potential not using a highly effective method of birth control.

         15. Patients who have taken an investigational drug within four weeks prior to Visit 1.

         16. Patients who have been treated with beta-blocker medication within four weeks prior to
             Visit 1 and/or during the screening period. Topical cardio-selective beta-blocker eye
             medications for non-narrow angle glaucoma are allowed.

         17. Patients who have been treated with the long-acting anticholinergic tiotropium
             (Spiriva®) within four weeks prior to Visit 1 and/or during the screening period.

         18. Patients who have been treated with oral or patch beta-adrenergics within four weeks
             prior to Visit 1 and/or during the Screening period.

         19. Patients who have been treated with oral corticosteroids within four weeks prior to
             Visit 1 and/or during the screening period.

         20. Patients who have been treated with anti-IgE antibodies, e.g. omalizumab (Xolair®),
             within 6 months prior to Visit 1 and/or during the screening period.

         21. Patients who have been treated with cromone within two weeks prior to Visit 1 and/or
             during the screening period.

         22. Patients who have been treated with methylxanthines or phosphodiesterase 4 inhibitors
             within two weeks prior to Visit 1 and/or during the screening period.

         23. Patients who have been treated with other non-approved and according to international
             guidelines not recommended &quot;experimental&quot; drugs for routine asthma therapy within four
             weeks prior to Visit 1 and/or during the screening period.

         24. Patients with any asthma exacerbation or any respiratory tract infection iin the four
             weeks prior to Visit 1 and/or during the screening period.

         25. Patients who have previously been randomised in this trial or in the respective twin
             trial (205.418) or are currently participating in another trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.419.01058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.01051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.55053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Florianopolis</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.55054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.55052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.55055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kunming</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.86068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yinchuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.57051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.57052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.57053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.57054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Medelin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.49055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.91057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.91056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.91055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.91051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.91058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.91054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.91059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mysore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.91053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nagpur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aira, Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuoka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81072 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuyama, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Habikino, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Itabashi-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iwata, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81063 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanazawa, Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kishiwada, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kitakyushu, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kobe, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Koto-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kyoto, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81080 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Matsusaka, Mie</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Meguro-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minato-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Morioka, Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naka-gun, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nakano-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oita,Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81068 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka-Sayama, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sendai, Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Seto, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinagawa-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyota, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Urasoe, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.81079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yotsukaido, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.52051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.52052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.52053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.51051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.51052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.51053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.51054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.51055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.48052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.48054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.48055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gorzow Wielkopolski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.48051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.48057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.48058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.48053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wloszczowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.48056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40053 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40054 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.419.40057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>India</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2010</study_first_submitted>
  <study_first_submitted_qc>July 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2010</study_first_posted>
  <results_first_submitted>October 25, 2013</results_first_submitted>
  <results_first_submitted_qc>January 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2014</results_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was 1 patient in the TIO R2.5 and 1 patient in the TIO R5 group randomized but not treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
        </group>
        <group group_id="P2">
          <title>Tio R2.5</title>
          <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P3">
          <title>Tio R5</title>
          <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="P4">
          <title>Salmeterol</title>
          <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="254">Entered and Treated</participants>
                <participants group_id="P2" count="257">Entered and Treated</participants>
                <participants group_id="P3" count="253">Entered and Treated</participants>
                <participants group_id="P4" count="266">Entered and Treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="240"/>
                <participants group_id="P2" count="245"/>
                <participants group_id="P3" count="240"/>
                <participants group_id="P4" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS) - all randomised patients who received at least 1 dose of randomised trial medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
        </group>
        <group group_id="B2">
          <title>Tio R2.5</title>
          <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B3">
          <title>Tio R5</title>
          <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="B4">
          <title>Salmeterol</title>
          <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="254"/>
            <count group_id="B2" value="257"/>
            <count group_id="B3" value="253"/>
            <count group_id="B4" value="266"/>
            <count group_id="B5" value="1030"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="13.0"/>
                    <measurement group_id="B2" value="43.0" spread="12.6"/>
                    <measurement group_id="B3" value="44.3" spread="12.7"/>
                    <measurement group_id="B4" value="41.5" spread="13.1"/>
                    <measurement group_id="B5" value="42.9" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="153"/>
                    <measurement group_id="B5" value="604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak FEV1 Within 3 Hours Post-dose Response</title>
        <description>Peak forced expiratory volume in one second (FEV1) response within 3 hours post-dose determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>24 weeks</time_frame>
        <population>Full Analysis Set (FAS) - all treated patients who had baseline data and at least 1 on-treatment efficacy measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 Within 3 Hours Post-dose Response</title>
          <description>Peak forced expiratory volume in one second (FEV1) response within 3 hours post-dose determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
          <population>Full Analysis Set (FAS) - all treated patients who had baseline data and at least 1 on-treatment efficacy measurement.</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.075" spread="0.020"/>
                    <measurement group_id="O2" value="0.287" spread="0.020"/>
                    <measurement group_id="O3" value="0.244" spread="0.020"/>
                    <measurement group_id="O4" value="0.252" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.211</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.159</ci_lower_limit>
            <ci_upper_limit>0.264</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.169</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.116</ci_lower_limit>
            <ci_upper_limit>0.222</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough FEV1 Response</title>
        <description>Trough FEV1 response determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response</title>
          <description>Trough FEV1 response determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.012" spread="0.021"/>
                    <measurement group_id="O2" value="0.164" spread="0.021"/>
                    <measurement group_id="O3" value="0.121" spread="0.021"/>
                    <measurement group_id="O4" value="0.094" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.029</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.120</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.133</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.029</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.076</ci_lower_limit>
            <ci_upper_limit>0.190</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FVC Within 3 Hours Post-dose Response</title>
        <description>Peak forced vital capacity (FVC) response within 3 hours post-dose determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FVC Within 3 Hours Post-dose Response</title>
          <description>Peak forced vital capacity (FVC) response within 3 hours post-dose determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.071" spread="0.022"/>
                    <measurement group_id="O2" value="0.181" spread="0.022"/>
                    <measurement group_id="O3" value="0.160" spread="0.022"/>
                    <measurement group_id="O4" value="0.188" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.110</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.052</ci_lower_limit>
            <ci_upper_limit>0.168</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0031</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.089</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.030</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.030</ci_lower_limit>
            <ci_upper_limit>0.147</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response</title>
        <description>Trough FVC response determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response</title>
          <description>Trough FVC response determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.048" spread="0.027"/>
                    <measurement group_id="O2" value="0.039" spread="0.027"/>
                    <measurement group_id="O3" value="0.035" spread="0.027"/>
                    <measurement group_id="O4" value="0.020" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, country, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0061</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.149</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, country, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 Area Under Curve 0-3 Hours (AUC0-3h) Response</title>
        <description>Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2) determined at the end of the 24- week treatment. Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Area Under Curve 0-3 Hours (AUC0-3h) Response</title>
          <description>Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2) determined at the end of the 24- week treatment. Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week. FEV1 AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>FAS</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.019"/>
                    <measurement group_id="O2" value="0.196" spread="0.019"/>
                    <measurement group_id="O3" value="0.158" spread="0.019"/>
                    <measurement group_id="O4" value="0.173" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.201</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>0.252</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.112</ci_lower_limit>
            <ci_upper_limit>0.215</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC Area Under Curve 0-3 Hours (AUC0-3h) Response</title>
        <description>Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2) determined at the end of the 24- week treatment. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>FVC Area Under Curve 0-3 Hours (AUC0-3h) Response</title>
          <description>Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2) determined at the end of the 24- week treatment. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week. FVC AUC 0-3h was calculated from 0-3 hours post-dose using the trapezoidal rule, divided by the observation time (3h) to report in litres.</description>
          <population>FAS</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.065" spread="0.024"/>
                    <measurement group_id="O2" value="0.043" spread="0.024"/>
                    <measurement group_id="O3" value="0.024" spread="0.025"/>
                    <measurement group_id="O4" value="0.066" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, country, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.108</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.029</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.052</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, country, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.089</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.029</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.033</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough PEF Response</title>
        <description>Trough peak expiratory flow (PEF) response determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Trough PEF Response</title>
          <description>Trough peak expiratory flow (PEF) response determined at the end of the 24-week treatment. Response was defined as change from baseline (10 minutes before the first dose of trial medication at visit 2). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>Litre/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.938" spread="3.659"/>
                    <measurement group_id="O2" value="36.698" spread="3.614"/>
                    <measurement group_id="O3" value="36.117" spread="3.646"/>
                    <measurement group_id="O4" value="29.352" spread="3.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28.759</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.963</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.025</ci_lower_limit>
            <ci_upper_limit>38.494</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.985</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.401</ci_lower_limit>
            <ci_upper_limit>37.956</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Asthma Quality of Life Questionnaire (AQLQs)) Score</title>
        <description>Total score from the Standardised Asthma Quality of Life Questionnaire (AQLQ(s)) determined at the end of 24-week treatment.
The AQLQ(s) contains 32 questions, each question has a 7 point scale from 1 (highest intensity) till 7 (no symptoms). Total score was defined as the sum of all items divided by the number of items and ranges from from 1 (highest intensity) till 7 (no symptoms). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Asthma Quality of Life Questionnaire (AQLQs)) Score</title>
          <description>Total score from the Standardised Asthma Quality of Life Questionnaire (AQLQ(s)) determined at the end of 24-week treatment.
The AQLQ(s) contains 32 questions, each question has a 7 point scale from 1 (highest intensity) till 7 (no symptoms). Total score was defined as the sum of all items divided by the number of items and ranges from from 1 (highest intensity) till 7 (no symptoms). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.551" spread="0.050"/>
                    <measurement group_id="O2" value="5.562" spread="0.049"/>
                    <measurement group_id="O3" value="5.548" spread="0.050"/>
                    <measurement group_id="O4" value="5.634" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8700</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.122</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9612</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.068</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.137</ci_lower_limit>
            <ci_upper_limit>0.130</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Asthma Control Questionnaire (ACQ) Score</title>
        <description>Control of asthma as assessed by the ACQ determined at the end of 24-week treatment. The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items and ranges from from 0 (no symptoms) till 6 (highest intensity). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Asthma Control Questionnaire (ACQ) Score</title>
          <description>Control of asthma as assessed by the ACQ determined at the end of 24-week treatment. The ACQ contains 7 questions, each question has a 7 point scale from 0 (no symptoms) till 6 (highest intensity). Total score was defined as the sum of all items divided by the number of items and ranges from from 0 (no symptoms) till 6 (highest intensity). Means are adjusted for treatment, centre, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="240"/>
                <count group_id="O4" value="250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.442" spread="0.043"/>
                    <measurement group_id="O2" value="1.315" spread="0.042"/>
                    <measurement group_id="O3" value="1.359" spread="0.043"/>
                    <measurement group_id="O4" value="1.318" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0305</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.127</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.241</ci_lower_limit>
            <ci_upper_limit>-0.012</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1602</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.059</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.198</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Responder Rate as Assessed by the ACQ</title>
        <description>The responder rate as assessed by the Asthma Control Questionnaire (ACQ) determined at the end of the 24-week treatment period. A patient was considered to be a responder if he or she was reported with an improvement (decrease) in ACQ total score of at least 0.5 points.The score ranges from 0 (no impairment) to 6 (maximum impairment).</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>The Responder Rate as Assessed by the ACQ</title>
          <description>The responder rate as assessed by the Asthma Control Questionnaire (ACQ) determined at the end of the 24-week treatment period. A patient was considered to be a responder if he or she was reported with an improvement (decrease) in ACQ total score of at least 0.5 points.The score ranges from 0 (no impairment) to 6 (maximum impairment).</description>
          <population>FAS</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="252"/>
                <count group_id="O4" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="66.4"/>
                    <measurement group_id="O3" value="61.9"/>
                    <measurement group_id="O4" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4012</p_value>
            <p_value_desc>Calculated as 2*one-sided-p-value in the direction corresponding to testing the null hypothesis</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
            <estimate_desc>Tio R2.5 / Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.1727</p_value>
            <p_value_desc>Calculated as 2*one-sided-p-value in the direction corresponding to testing the null hypothesis</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>Tio R5 / Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Morning PEF (PEF a.m.) Based on the Weekly Mean Response at Week 24</title>
        <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week</description>
        <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Morning PEF (PEF a.m.) Based on the Weekly Mean Response at Week 24</title>
          <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week</description>
          <population>FAS</population>
          <units>Litre/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.764" spread="3.292"/>
                    <measurement group_id="O2" value="23.377" spread="3.267"/>
                    <measurement group_id="O3" value="27.521" spread="3.294"/>
                    <measurement group_id="O4" value="19.779" spread="3.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>20.613</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.496</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.795</ci_lower_limit>
            <ci_upper_limit>29.431</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>24.757</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.513</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.907</ci_lower_limit>
            <ci_upper_limit>33.607</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Evening PEF (PEF p.m.) Based on the Weekly Mean Response at Week 24</title>
        <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Evening PEF (PEF p.m.) Based on the Weekly Mean Response at Week 24</title>
          <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>Litre/min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.072" spread="3.328"/>
                    <measurement group_id="O2" value="15.919" spread="3.303"/>
                    <measurement group_id="O3" value="21.175" spread="3.330"/>
                    <measurement group_id="O4" value="11.617" spread="3.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.991</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.547</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.074</ci_lower_limit>
            <ci_upper_limit>24.908</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>21.247</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.561</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.302</ci_lower_limit>
            <ci_upper_limit>30.193</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PEF Variability</title>
        <description>PEF daily variability was assesed by patients at home using the AM3 device. PEF variability is the absolute difference between morning and evening PEF value divided by their mean, based on the weekly mean response at week 24. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>Last 7 days before week 24 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>PEF Variability</title>
          <description>PEF daily variability was assesed by patients at home using the AM3 device. PEF variability is the absolute difference between morning and evening PEF value divided by their mean, based on the weekly mean response at week 24. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>Percentage of Mean PEF</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.448" spread="0.484"/>
                    <measurement group_id="O2" value="-1.401" spread="0.480"/>
                    <measurement group_id="O3" value="-0.627" spread="0.487"/>
                    <measurement group_id="O4" value="-1.518" spread="0.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, country, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1114</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.953</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.598</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.125</ci_lower_limit>
            <ci_upper_limit>0.220</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, country, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7665</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.178</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.600</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.355</ci_lower_limit>
            <ci_upper_limit>0.999</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Morning FEV1 (FEV1 a.m.) Based on the Weekly Mean Response at Week 24</title>
        <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Morning FEV1 (FEV1 a.m.) Based on the Weekly Mean Response at Week 24</title>
          <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.020" spread="0.023"/>
                    <measurement group_id="O2" value="0.099" spread="0.023"/>
                    <measurement group_id="O3" value="0.084" spread="0.023"/>
                    <measurement group_id="O4" value="0.103" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0111</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.079</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0395</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.031</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pre-dose Evening FEV1 (FEV1 p.m.) Based on the Weekly Mean Response at Week 24</title>
        <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pre-dose Evening FEV1 (FEV1 p.m.) Based on the Weekly Mean Response at Week 24</title>
          <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>Litre</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.024"/>
                    <measurement group_id="O2" value="0.066" spread="0.023"/>
                    <measurement group_id="O3" value="0.064" spread="0.024"/>
                    <measurement group_id="O4" value="0.048" spread="0.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0357</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, centre, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0422</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.066</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.032</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.129</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Puffs of Rescue Medication During the Entire 24-h Day Based on the Weekly Mean Response at Week 24</title>
        <description>Daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
        <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Puffs of Rescue Medication During the Entire 24-h Day Based on the Weekly Mean Response at Week 24</title>
          <description>Daily use of salbutamol (albuterol) rescue medication as needed during the entire study period. Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week.</description>
          <population>FAS</population>
          <units>Number of Puffs</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.952" spread="0.093"/>
                    <measurement group_id="O2" value="-1.123" spread="0.092"/>
                    <measurement group_id="O3" value="-0.843" spread="0.093"/>
                    <measurement group_id="O4" value="-1.078" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1927</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.171</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.131</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.427</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4053</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.109</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.131</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.148</ci_lower_limit>
            <ci_upper_limit>0.367</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom-free Days Based on the Weekly Mean Response at Week 24</title>
        <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week. An asthma symptom-free day was defined as a day with no reported symptoms and no use of rescue medication.</description>
        <time_frame>Baseline and last 7 days before week 24 visit</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom-free Days Based on the Weekly Mean Response at Week 24</title>
          <description>Weekly means obtained during the last 7 days before week 24 measured by patients at home using the AM3 device. Response was defined as change from baseline. Means are adjusted for treatment, country, week, baseline, treatment by week, and baseline by week. An asthma symptom-free day was defined as a day with no reported symptoms and no use of rescue medication.</description>
          <population>FAS</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="238"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.189" spread="0.023"/>
                    <measurement group_id="O2" value="0.164" spread="0.023"/>
                    <measurement group_id="O3" value="0.196" spread="0.023"/>
                    <measurement group_id="O4" value="0.195" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, country, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3501</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.079</ci_lower_limit>
            <ci_upper_limit>0.028</ci_upper_limit>
            <estimate_desc>Tio R2.5 - Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analyses included the fixed, categorical effects of treatment, country, week, and treatment-by-week interaction, as well as the covariates of baseline value and baseline value-by-week interaction. Patient was included as a random effect in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8045</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Adjusted using a restricted maximum likelihood (REML)-based mixed effects model with repeated measures (MMRM).</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.028</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.047</ci_lower_limit>
            <ci_upper_limit>0.061</ci_upper_limit>
            <estimate_desc>Tio R5 - Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Responder Rate as Assessed by the ACQ From the Two Twin Trials 205.418 (NCT01172808) and the Present 205.419 (NCT01172821)</title>
        <description>The responder rate as assessed by the Asthma Control Questionnaire (ACQ) determined at the end of the 24-week treatment period (on combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)). A patient was considered to be a responder if he or she was reported with an improvement (decrease) in the ACQ total score of at least 0.5 points.</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS of combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>The Responder Rate as Assessed by the ACQ From the Two Twin Trials 205.418 (NCT01172808) and the Present 205.419 (NCT01172821)</title>
          <description>The responder rate as assessed by the Asthma Control Questionnaire (ACQ) determined at the end of the 24-week treatment period (on combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)). A patient was considered to be a responder if he or she was reported with an improvement (decrease) in the ACQ total score of at least 0.5 points.</description>
          <population>FAS of combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="515"/>
                <count group_id="O3" value="513"/>
                <count group_id="O4" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7"/>
                    <measurement group_id="O2" value="64.5"/>
                    <measurement group_id="O3" value="64.3"/>
                    <measurement group_id="O4" value="66.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0308</p_value>
            <p_value_desc>Calculated as 2*one-sided-p-value in the direction corresponding to testing the null hypothesis</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.72</ci_upper_limit>
            <estimate_desc>Tio R2.5 / Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0348</p_value>
            <p_value_desc>Calculated as 2*one-sided-p-value in the direction corresponding to testing the null hypothesis</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>Tio R5 / Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Severe Asthma Exacerbation From the Two Twin Trials 205.418 (NCT01172808) and the Present 205.419 (NCT01172821)</title>
        <description>Time to first severe asthma exacerbation during the 24-week treatment period on combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS of combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Severe Asthma Exacerbation From the Two Twin Trials 205.418 (NCT01172808) and the Present 205.419 (NCT01172821)</title>
          <description>Time to first severe asthma exacerbation during the 24-week treatment period on combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</description>
          <population>FAS of combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="515"/>
                <count group_id="O3" value="513"/>
                <count group_id="O4" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median time to first severe asthma exacerbation could not be calculated as less than 50% of patients in each treatment group experienced an asthma exacerbation.</measurement>
                    <measurement group_id="O2" value="NA">The median time to first severe asthma exacerbation could not be calculated as less than 50% of patients in each treatment group experienced an asthma exacerbation.</measurement>
                    <measurement group_id="O3" value="NA">The median time to first severe asthma exacerbation could not be calculated as less than 50% of patients in each treatment group experienced an asthma exacerbation.</measurement>
                    <measurement group_id="O4" value="NA">The median time to first severe asthma exacerbation could not be calculated as less than 50% of patients in each treatment group experienced an asthma exacerbation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Asthma Exacerbation From the Two Twin Trials 205.418 (NCT01172808) and the Present 205.419 (NCT01172821)</title>
        <description>Time to first asthma exacerbation (including severe, non-severe; symptomatic, asymptomatic; i.e. any exacerbation) during the 24-week treatment period on combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</description>
        <time_frame>24 weeks</time_frame>
        <population>FAS of combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
          <group group_id="O2">
            <title>Tio R2.5</title>
            <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tio R5</title>
            <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Salmeterol</title>
            <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Asthma Exacerbation From the Two Twin Trials 205.418 (NCT01172808) and the Present 205.419 (NCT01172821)</title>
          <description>Time to first asthma exacerbation (including severe, non-severe; symptomatic, asymptomatic; i.e. any exacerbation) during the 24-week treatment period on combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</description>
          <population>FAS of combined data from the two twin trials 205.418 (NCT01172808) and 205.419 (NCT01172821)</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="515"/>
                <count group_id="O3" value="513"/>
                <count group_id="O4" value="535"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median time to first asthma exacerbation could not be calculated as less than 50% of patients in each treatment group experienced an asthma exacerbation.</measurement>
                    <measurement group_id="O2" value="NA">The median time to first asthma exacerbation could not be calculated as less than 50% of patients in each treatment group experienced an asthma exacerbation.</measurement>
                    <measurement group_id="O3" value="NA">The median time to first asthma exacerbation could not be calculated as less than 50% of patients in each treatment group experienced an asthma exacerbation.</measurement>
                    <measurement group_id="O4" value="NA">The median time to first asthma exacerbation could not be calculated as less than 50% of patients in each treatment group experienced an asthma exacerbation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo delivered by the Respimat Inhaler resp. MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
        </group>
        <group group_id="E2">
          <title>Tio R2.5</title>
          <description>Tiotropium 2.5 microgram (mcg) qd (evening) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Tio R5</title>
          <description>Tiotropium 5 mcg qd (evening) delivered by the Respimat Inhaler.</description>
        </group>
        <group group_id="E4">
          <title>Salmeterol</title>
          <description>Salmeterol 50 mcg bid (morning and evening) delivered by the MDI (hydrofluoroalkane (HFA 134a) metered inhaler).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Parovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Eosinophilic pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="266"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Peak expiratory flow rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="257"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="253"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="266"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

